The Prolonged Use of Topiramate for Preventing Migraine Headaches

Migraine Clinical Trial

— PROMPT  

Official title:

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Investigate the Efficacy and Tolerability of Topiramate in Prolonged Migraine Prevention

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00216619
• Other study ID #: CR003931
• Secondary ID: 2005-000321-29TO
• Status: Completed
• Phase: Phase 3
• First received: September 13, 2005
• Last updated: July 1, 2014
• Start date: November 2003
• Est. completion date: August 2006

Study information

• Verified date: July 2014
• Source: Janssen Pharmaceutica N.V., Belgium
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Ministry of Social Affairs, Public Health and the Environment
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness (beyond 6 months) of individualized doses (100 to 200 milligrams) of topiramate for the prevention of migraine headaches over a period of 26 weeks.

Description:

Previous studies have shown that topiramate is effective in preventing migraine headaches. This study will start with a 4-week baseline period in which no treatment is given, followed by a 26-week period in which each patient's dose is adjusted and then kept stable for 4 weeks. The dose will start at 25 milligrams of topiramate per day and will be increased 25 milligrams per day once weekly and then raised to either the target--100 milligrams per day--or the maximum dose that is well tolerated up to 200 milligrams per day. Patients randomized to receive topiramate will remain on that dose. The comparison phase of the study is a 26-week period in which the change in migraine days of patients on topiramate (taking at least 50 milligrams per day) is compared with the change in migraine days for patients on the placebo. Also studied will be the patients' health-related quality of life as assessed by questionnaires filled out at specific visits as well as the patients' views of the safety and tolerability of topiramate. The study hypothesis is that the number of migraine days, periods, and attacks during the last 4 weeks of the double-blind phase, relative to the last 4 weeks of the open-label phase, is reduced more in the topiramate group than the placebo group. During open-label (26-weeks) and double-blind phase (26-weeks), patients receiving topiramate will take 25 milligrams to 100 milligrams daily by mouth; increased by 25 milligrams per day once weekly; dose cannot exceed 200 milligrams per day and must be stable for the last 4 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 834
• Est. completion date: August 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Established history of migraine for at least one year;

• Migraine meets HIS (International Headache Society) criteria

• An average of at least 4 monthly migraine days during the 3 months preceding trial entry

• Capable of keeping trial records; Exclusion Criteria:

• Patient used migraine prophylactic medication in the month prior to trial entry (flunarizine: 3 months prior to entry)

• Patient had failed (lack of efficacy) more than two adequate previous regimens of migraine prophylactic medications

• Patient had a history of severe drug allergy or hypersensitivity

• Patient overused analgesics, opiates, ergots and/or triptans

• Patient had been using topiramate regularly

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Migraine
• Migraine Disorders

Intervention

Drug:
• Topiramate
topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening.
• Topiramate - Placebo
the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Janssen Pharmaceutica N.V., Belgium

Countries where clinical trial is conducted

Austria,  Belgium,  Bulgaria,  Czech Republic,  Denmark,  France,  Germany,  Greece,  Hungary,  Ireland,  Norway,  Poland,  Portugal,  Russian Federation,  Saudi Arabia,  Slovenia,  Spain,  Switzerland,  Turkey,  United Kingdom, 

References & Publications (1)

Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B, Ertas M, Lanteri-Minet M, Reuter U, Sánchez Del Río M, Schoenen J, Schwalen S, van Oene J; TOPMAT-MIG-303 Investigators Group. Cessation versus continuation of 6-month migraine preventive the — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in migraine days compared between the topiramate group and placebo group at the last 4 weeks of the open-label phase and the final 4 weeks of the placebo-controlled phase		Last 4 weeks of Open Label (OL) Phase and Double Blind (DB) Phase	No
Secondary	Patient's Satisfaction	at the end of the OL Phase and at the end of the DB Phase	Visit 6	No
Secondary	Health related quality of life as recorded in patient questionnaires (MIDAS and SF-12)	At the start of the OL Phase; at the end of the of the OL Phase and at the end of the DB Phase	Visit 2, Visit 6, Visit 10	No
Secondary	Health related quality of life as recorded in patient questionnaire (HIT-6)	HIT-6 extra questioned at Week 8 and Week 34	Visit 2, Visit 4, Visit 6, Visit 8, Visit 10	No

External Links

•   A double-blind, randomised, placebo-controlled, multicentre study to investigate the efficacy and tolerability of topiramate in prolonged migraine prevention.